<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05026970</url>
  </required_header>
  <id_info>
    <org_study_id>16/19</org_study_id>
    <nct_id>NCT05026970</nct_id>
  </id_info>
  <brief_title>Validation of a Multimodal Algorithm for the Treatment of Fecal Incontinence</brief_title>
  <official_title>Validation of a Multimodal Algorithm for Treatment of Fecal Incontinence in Women: Study of the Efficacy of the Combination of Treatments on the Impact on Clinical Severity and Quality of Life, and on the Underlying Pathophysiology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital de Mataró</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital de Mataró</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Thisi is a pragmatical clinical trial with the main aim of main aim of evaluating the&#xD;
      effectiveness of the combination of treatments for the management of fecal incontinence (FI),&#xD;
      on profiles of patients with IF based on pathophysiological criteria, measuring&#xD;
      physiological, clinical and quality of life outputs.&#xD;
&#xD;
      Secondary:&#xD;
&#xD;
        1. Evaluate the presence of SIBO, gluten-sensitive enteropathy, malabsorption of bile salts&#xD;
           or sugars in patients with Bristol stools ≥5 that condition the fecal continuity.&#xD;
&#xD;
        2. Effect of change in fecal consistency on IF symptoms.&#xD;
&#xD;
        3. To evaluate the effect of the combination of treatments on anorectal physiology and&#xD;
           neurophysiology (motor and sensory), clinical severity and quality of life.&#xD;
&#xD;
        4. Evaluate the persistence of the treatments to the three months of end of the same.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      FI is a very prevalent condition in community dwelling women. We have previously studied the&#xD;
      efectivenes of four treatments in women with FI as well as the effect on the anorectal&#xD;
      physiology and neurophysiology. All treatments improved clinical symptoms of FI but there&#xD;
      were no statistical differences between the treatments, that were Kegel exercises (K),&#xD;
      biofeedback (BF)+K, electrostimulation (ES)+K, and transcutaneous neuromodulation (tNM)+K.&#xD;
      With this prevoous study we have a clearer idea of the anorectal physiology which should&#xD;
      allow to select patients for given treatments.&#xD;
&#xD;
      For the present study we try to validate a multimodal algorithm to treat FI, taking into&#xD;
      account the underlying pahtophysiology.&#xD;
&#xD;
      It will have 2 differentiated stages:&#xD;
&#xD;
      Stage 1: Patients with loose stools (Bristol &gt;5): they will be studied to determine the cause&#xD;
      of the diahrrea (mainly food intolerances) and treated accordingly. If FI symptoms remain,&#xD;
      patients will pass to:&#xD;
&#xD;
      Stage 2: Patients with Bristol&lt;6 anf FI symptoms. They will be adressed to 3 combinations of&#xD;
      treatments according to the pathophysiology that explain the symptoms, which will be:&#xD;
&#xD;
      BF+ES+K: those patients with direct sphincter damage BF+tNM+K: patients with external anal&#xD;
      sphincter dennervation and/or colonic motility disorders.&#xD;
&#xD;
      BF alones: patients with FI mainly explained by a bad control of the pelvic floor function&#xD;
      (akinesia/dyssynergia).&#xD;
&#xD;
      All patients will be studied with High Resolution Anorectal Manometry, PNTML, endoanal&#xD;
      unltrasonography. Clinical severity and QoL with dedicated intruments or questionnaires.&#xD;
&#xD;
      If after 1sr stage, if so, patients have a clinical severity of Cleveland&lt;4 they will be&#xD;
      followed up at 3 months with K, studued again their clinical severity and QoL.&#xD;
&#xD;
      After 2nd stage, if so, 3-month of targeted treatment will be performed, and reevaluated with&#xD;
      HRAM, PNTML and clinical questionnaires. They will be followed up at 3 monts with only K to&#xD;
      study the persistance of the treatments.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2019</start_date>
  <completion_date type="Anticipated">May 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cleveland Severity Score</measure>
    <time_frame>3 month and 6 month</time_frame>
    <description>Changes in clinical severity after the treatments measured with Cleveland score, which ranges from 0 (total continence) to 20 (very severe incontinence)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anorectal physiology (motor)</measure>
    <time_frame>3 month and 6 month</time_frame>
    <description>Changes in anal mean resting pressure and squeeze (voluntary) pressure after the treatments measured with mmHg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anorectal physiology (sensorial)</measure>
    <time_frame>3 month and 6 month</time_frame>
    <description>Changes in rectal sensory thresholds after the treatments measured in volume (milliliters) of rectal distention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anorectal neurophysiology</measure>
    <time_frame>3 month and 6 month</time_frame>
    <description>Changes in pudendal nerve terminal motor latency (PNTML) measured with milliseconds</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of Life (QoL) according to FIQL scale</measure>
    <time_frame>3 month and 6 month</time_frame>
    <description>Improvements in Fecal incontinence-related QoL after the treatments</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Fecal Incontinence</condition>
  <arm_group>
    <arm_group_label>Biofeedback+Electrostimulation+Kegel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Biofeedback (3 sessions) Electrostimulation (12 weeks daily treatment) Kegel exercises (twice daily)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Biofeedback+Tibial Neuromodulation+Kegel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Biofeedback (3 sessions) Transcutaneous Neuromodulation (12 weeks daily treatment) Kegel exercises (twice daily)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Biofeedback+Kegel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Biofeedback (6 sessions) Kegel exercises (twice daily)</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Biofeedback+Electrostimulation+Kegel</intervention_name>
    <description>Biofeedback (3 sessions) Electrostimulation (12 weeks daily treatment) Kegel exercises (twice daily)</description>
    <arm_group_label>Biofeedback+Kegel</arm_group_label>
    <arm_group_label>Biofeedback+Tibial Neuromodulation+Kegel</arm_group_label>
    <other_name>BF+ES+K</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Biofeedback+Tibial Neuromodulation+Kegel</intervention_name>
    <description>Biofeedback (3 sessions) Transcutaneous Neuromodulation (12 weeks daily treatment) Kegel exercises (twice daily)</description>
    <arm_group_label>Biofeedback+Electrostimulation+Kegel</arm_group_label>
    <arm_group_label>Biofeedback+Kegel</arm_group_label>
    <other_name>BF+tNM+K</other_name>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Biofeedback+Kegel</intervention_name>
    <description>Biofeedback+Kegel exercises</description>
    <arm_group_label>Biofeedback+Electrostimulation+Kegel</arm_group_label>
    <arm_group_label>Biofeedback+Tibial Neuromodulation+Kegel</arm_group_label>
    <other_name>BF+K</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  FI episodes at least 6 months before&#xD;
&#xD;
          -  FI episodes each month&#xD;
&#xD;
          -  No other treatment the year before&#xD;
&#xD;
          -  Able to self-administer treatments&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  If, to investigators criteria, patient will fail to administer the tratmetns properly,&#xD;
             due to physical or psychic conditions&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alba Raventós, Nurse</last_name>
    <phone>937417700</phone>
    <phone_ext>2748</phone_ext>
    <email>albar.ravens92@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lluís Mundet</last_name>
    <email>lluismundetp@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital de Mataró</name>
      <address>
        <city>Mataró</city>
        <state>Barcelona</state>
        <zip>08304</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lluís Mundet</last_name>
      <phone>937417700</phone>
      <phone_ext>2756</phone_ext>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 13, 2020</study_first_submitted>
  <study_first_submitted_qc>August 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2021</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital de Mataró</investigator_affiliation>
    <investigator_full_name>Lluís Mundet</investigator_full_name>
    <investigator_title>Motility Unit Coordinator</investigator_title>
  </responsible_party>
  <keyword>fecal incontinence</keyword>
  <keyword>anorectal physiology</keyword>
  <keyword>pragmatic clinical trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fecal Incontinence</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

